Organic Process Research & Development 2010, 14, 553–561
Kilogram Synthesis of a LFA-1/ICAM Inhibitor
Albert J. DelMonte,* Robert E. Waltermire, Yu Fan, Douglas D. McLeod, Zhinong Gao, Kirsten D. Gesenberg,
Kevin P. Girard, Miguel Rosingana, Xuebao Wang, Jennifer Kuehne-Willmore, Alan D. Braem, and John A. Castoro
Process Research and DeVelopment, Bristol-Myers Squibb Company, One Squibb DriVe, P.O. Box 191,
New Brunswick, New Jersey 08903-0191, U.S.A.
Abstract:
Results and Discussion
The original synthesis of 1 by our Discovery colleagues
provided the multigram quantities required for preclinical
development studies (Scheme 1).4,5 This route featured a
stereospecific [3 + 2] cycloaddition of olefin 3 with N-
(methoxymethyl)-N-(trimethylsilylmethyl)benzylamine to afford
a single diastereomer of the spirocyclic core in a racemic
fashion, with the olefin geometry establishing the relative stereo-
chemistry of 4. Deprotection of the resulting N-benzyl pyrro-
lidine afforded the racemic secondary amine 5.6 The desired
single enantiomer was obtained by a chiral chromatographic
separation using supercritical fluid chromatography (SFC). The
final step in the synthesis was reductive amination with
5-formyl-3-thiophenecarboxylic acid.
In order to support the synthesis of kilogram quantities of
API for clinical development, a shorter and more efficient route
to 1 was desired. As shown in the retrosynthetic analysis (Figure
1) our strategy centered on retaining the powerful [3 + 2]
cycloaddition approach to assemble the spirocyclic core and,
at the same time, eliminating or minimizing the employment
of protecting groups and chromatography. Ideally, the unpro-
tected spirocyclic hydantoin 5 would be directly obtained by a
The process development and the kilogram-scale synthesis of BMS-
587101 (1) are described. The synthesis features a [3 + 2]
azomethine ylide cycloaddition to efficiently build the spirocyclic
core in a diastereoselective fashion followed by a classical resolution
which affords the desired enantiomer in >98% enantiomeric
excess. The target was prepared in four steps in an overall yield
of 22%.
Introduction
Interaction between leukocyte function-associated antigen-1
(LFA-1), expressed on the surface of cytokine-stimulated cells,
and intercellular adhesion molecule (I-CAM), found on the
surface of both leukocytes and endothelium, plays a key function
in the intercellular immune response, causing T-cell adhesion
and subsequent migration through the blood vessel wall to the
inflamed area.1 Small molecules which inhibit the LFA-1/I-
CAM interaction are targeted as potential drugs for the treatment
of a variety of autoimmune and inflammatory diseases such as
rheumatoid arthritis and psoriasis.2,3 The LFA-1 receptor antag-
onist, BMS-587101, 1,4,5 was selected for clinical development,
and we required a synthesis that would reliably generate
kilogram quantities of API. This paper details the identification
and development of a synthesis which enabled the realization
of this goal.
(4) The Discovery work towards this target compound BMS-587101 is
described in: Potin, D.; Launay, M.; Monatlik, F.; Malabre, P.;
Fabreguettes, M.; Fouquet, A.; Maillet, M.; Nicolai, E.; Dorgeret, L.;
Chevallier, F.; Besse, D.; Dufort, M.; Caussade, F.; Ahmad, S. Z.;
Stetsko, D. K.; Skala, S.; Davis, P. M.; Balimane, P.; Patel, K.; Yang,
Z.; Marathe, P.; Postelneck, J.; Townsend, R. M.; Goldfarb, V.; Sheriff,
S.; Einspahr, H.; Kish, K.; Malley, M. F.; DiMarco, J. D.; Gougoutas,
J. Z.; Kadiyala, P.; Cheney, D. L.; Tejwani, R. W.; Murphy, D. K.;
Mcintyre, K. W.; Yang, X.; Chao, S.; Leith, L.; Xiao, Z.; Mathur, A.;
Chen, B.-C.; Wu, D.-R.; Traeger, S. C.; McKinnon, M.; Barrish, J. C.;
Robl, J. A.; Iwanowicz, E. J.; Suchard, S. J.; Dhar, M. T. G. J. Med.
Chem. 2006, 49, 6946.
* Author for correspondence.
(1) For a discussion on the inhibition of LFA-1/ICAM-1as an approach
to treating autoimmune diseases see: Yusuf-Makagiansar, H.; Ander-
son, M. E.; Yakovleva, T. V.; Murray, J. S.; Siahaan, T. J. Medicinal
Research ReViews 2002, 22, 146.
(2) For a discussion of therapeutic options for treatment of psoriasis, see:
Gottlieb, A. B. J. Acad. Dermatol 2005, 53, S3. Larson, R. S.; Davis,
T.; Bologa, C.; Semenuk, G.; Vijayan, S.; Li, Y.; Oprea, T.; Chigaev,
A.; Buranda, T.; Wagner, C. R.; Sklar, L. A.
(5) For additional information related to this compound see: (a) Chen,
B.-C.; DelMonte, A. J.; Dhar, T. G. M.; Fan, Y.; Gougoutas, J. Z.;
Malley, M. F.; McLeod, D. D.; Waltermire, R.; Wei, C. Crystalline
Forms and Process for Preparing Spiro-Hydantoin Compounds.
(Bristol-Myers Squibb). U.S. Patent 7,381,737 B2 . (b) Dhar, T. G. M.;
Potin, D.; Maillet, M.; Launay, M.; Nicolai, E.; Iwanowicz, E. Spiro-
cyclic compounds useful as anti-inflammatory agents. Bristol-Myers
Squibb and Cerep). U.S. Patent 7,199,125 B2. (c) Launay, M.; Potin,
D.; Maillet, M.; Nicolai, E.; Dhar, T. G. M.; Iwanowicz, E. Hydantoin
compounds useful as anti-inflammatory agents. (Bristol-Myers Squibb).
U.S. Patent 6,710,064 B2. For the radiolabelled synthesis of BMS-
587101 see: Tran, S. B.; Maxwell, B. D.; Chen, S.-Y.; Bonacorsi,
S. J.; Leith, L.; Ogan, M.; Rinehart, J. K.; Balasubramanian, B.
J. Labelled Compd. Radiopharm. 2009, 52, 236.
(3) For other small molecule LFA-1/ICAM-1 antagonists as potential drugs
please see: (a) Pei, Z.; Xin, Z.; Liu, G.; Li, Y.; Reilly, E. B.; Lubbers,
N. L.; Huth, J. R.; Link, J. T.; von Geldern, T. W.; Cox, B. F.; Leitza,
S.; Gao, Y.; Marsh, K. C.; DeVries, P.; Okasinski, G. F. J. Med. Chem.
2001, 44, 2913. (b) Liu, G.; Huth, J. R.; Olejniczak, E. T.; Mendoza,
R.; DeVries, P.; Leitza, S.; Reilly, E. B.; Olasinski, G. F.; Fesik, S. W.;
von Geldern, T. W. J. Med. Chem. 2001, 44, 1202. (c) Wu, J.-P.;
Emeigh, J.; Gao, D. A.; Goldberg, D. R.; Kuzmich, D.; Miao, C.;
Potocki, I.; Qian, K. C.; Sorcek, R. J.; Jeanfavre, D. D.; Kishimoto,
K.; Mainolfi, E. A.; Nabozny, G.; Peng, C.; Reilly, P.; Rothlein, R.;
Sellati, R. H.; Woska, J. R.; Chen, S.; Gunn, J. A.; O’Brien, D.; Norris,
S. H.; Kelly, T. A. J. Med. Chem. 2004, 47, 5356. (d) Last-Barney,
K.; Davidson, W.; Cardozo, M.; Frye, L. L.; Grygon, C. a.; Hopkins,
J. L.; Jeanfavre, D. D.; Pav, S.; Qian, C.; Stevenson, J. M.; Tong, L.;
Zindell, R.; Kelly, T. A. J. Am. Chem. Soc. 2001, 123, 5643. (e) Wang,
G. T.; Wang, S.; Gentles, R.; Sowin, T.; Leitza, S.; Reilly, E. B.; von
Geldern, T. W. Bioorg. Med. Chem. Lett. 2005, 15, 195. (f) Wattanasin,
S.; Albert, R.; Ehrhardt, C.; Roche, D.; Savio, M.; Hommel, U.;
Welzenbach, K.; Weitz-Schmidt, G. Bioorg. Med. Chem. Lett. 2003,
12, 499.
(6) While effective at removing the benzyl group, avoiding the use of
1-chloroethyl chloroformate in dichloroethane was highly desirable
since use of these reagents would raise concerns about genotoxic
impurity formation.
(7) Throughout this paper when the molecule is a racemic mixture of a
single diastereomer, solid and dashed rectangular bonds are used to
convey relative stereochemistry. When the compound is a single
enantiomer, solid and dashed wedged bonds are used to convey
absolute stereochemistry.
10.1021/op9003168 2010 American Chemical Society
Published on Web 03/10/2010
Vol. 14, No. 3, 2010 / Organic Process Research & Development
•
553